Androgen replacement therapy in women: Myths and realities

International Journal of Fertility and Menopausal Studies

Volumn 41, Issue 4, 1996, Pages 412-422

  Casson, Peter R ^a   Carson, Sandra A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

androgen; dehydroepiandrosterone; menopause; testosterone

Indexed keywords

ANDROGEN; ANDROSTANOLONE; ANDROSTENEDIONE; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; HYDROCORTISONE; LUTEINIZING HORMONE; METHYLTESTOSTERONE; PLACEBO; PRASTERONE; PRASTERONE SULFATE; TESTOSTERONE; TESTOSTERONE ENANTATE;

AGING; ARTICLE; CLINICAL TRIAL; COGNITION; DRUG BIOAVAILABILITY; FEMALE; HEART PROTECTION; HIRSUTISM; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; IMMUNOMODULATION; INSULIN SENSITIVITY; INTRAMUSCULAR DRUG ADMINISTRATION; MENOPAUSE; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TRANSDERMAL DRUG ADMINISTRATION; VIRILIZATION;

ADRENAL GLANDS; AGING; ANDROGENS; COGNITION; DEHYDROEPIANDROSTERONE; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; IMMUNE SYSTEM; MENOPAUSE; SEX CHARACTERISTICS;

EID: 0029827995     PISSN: 10693130     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Clark JH, Schrader WT, O'Malley BW: Mechanisms of action of steroid hormones, in Wilson JD, Foster
2. DW (eds): Williams Textbook of Endocrinology. Philadelphia, W.B. Saunders, pp 35-90, 1992.
3. Pavlou SN, Brewer K, Parley MG, et al: Combined administration of gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. J Clin Endocrinol Metab 73:1360-1369, 1991.
4. Speroff L, Glass RH, Käse NG: Hirsutism: the biology of hair growth; the diagnosis and management of hirsutism, in Speroff L, Glass RH, Käse NG (eds): Clinical Gynecologic Endocrinology and Infertility. Baltimore, Williams & Wilkins, pp 201-224, 1994.
5. Griffin JE, Wilson JD: Disorders of the testes and the male reproductive tract, in Wilson JD, Foster DW (eds): Williams Textbook of Endocrinology. Philadelphia, W.B. Saunders, pp 779-852, 1992.
6. Kennedy BJ, Gilbertsen AS: Increased erthropoiesis induced by androgenic-hormone therapy. N Engl J Med 256:719-726, 1957.
7. Naftolin F: Brain aromatization of androgens. J Reprod Med 39:257:257-261, 1994.
8. Abraham GE: Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle. J Clin Endocrinol Metab 39:340, 1974.
9. Yen SSC: Chronic anovulation caused by peripheral endocrine disorders, in Yen SSC, Jaffe RB (eds): Reproductive Endocrinology. Philadelphia, W.B. Saunders, pp 576-630, 1991.
10. Casson PR, Buster JE: DHEA administration to humans: panacea or palaver? Sem Reprod Endocrinol 13(4):247-256, 1995.
11. Haning RV, Chabot M, Hackett R, et al: Metabolie clearance rate (MCR) of dehydroepiandrosterone sulfate (DS), its metabolism to dehydroepiandrosterone, androstenedione, testosterone, and dihydrotestosterone, and the effect of increased plasma DS concentration on DS MCR in normal women. J Clin Endocrinol Metab 69:1047-1052, 1989.
12. Orentreich N, Brind JL, Rizer RL, et al: Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 59:551-555, 1984.
13. Longcope C, Hunter R, Franz C: Steroid secretion by the postmenopausal ovary. Am J Obstet Gynecol 248:564-568, 1980.
14. Meldrum DR, Davidson BJ, Tatazryn IV, et al: Changes in circulating steroids with aging in postmenopausal women. Obstet Gynecol 57:624-628, 1981.
15. Chakravarti S, Collins WP, Forecast JD, et al: Hormonal profiles after the menopause. Br Med J 2:784-786, 1976.
16. Tazuke S, Khaw KT, Barrett-Connor E: Exogenous estrogen and endogenous sex hormones. Medicine 71:44-50, 1992.
17. Judd HL, Judd GE, Lucas WE, et al: Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. J Clin Endocrinol Metab 39:1020, 1974.
18. Nahrendorf G, Carol W, Klinger G: Effect of oral contraceptives on the psyche and on sexuality. Zentmlblatt für Gynäkologie 100:632-637, 1978.
19. Raboch J, Kobilkova J, Starka L: Sexual life of women with Stein-Leventhal syndrome. Archiv Sex Behav 14:263-270, 1985.
20. Mathews A, Whitehead A, Kellett J: Psychological and hormonal factors in the treatment of female sexual dysfunction. Phychol Med 13:83-92, 1983.
21. Greenblatt RB, Barfield WE, Garner JF, et al: Evaluation of an estrogen, androgen, estrogen-androgen combination, and a placebo in the treatment of the menopause. J Clin Endocrinol 10:1547-1558, 1950.
22. Sherwin BB, Gelfand MM: Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol 151:153-160, 1985.
23. Sherwin BB, Gelfand MM: The role of androgens in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 49:397-409, 1987.
24. Urman B, Pride SM, Yuen BH: Elevated serum testosterone, hirsutism, and virilism associated with combined androgen-estrogen hormone replacement therapy. Obstet Gynecol 77:595-598, 1991.
25. Myers LS, Dixen J, Morrissette D, et al: Effects of estrogen, androgen, and progestin on sexual psychophysioloigy and behavior in postmenopausal women. J Clin Endocrinol Metab 70:1124-1131, 1990.
26. Colvard DS, Eriksen EF, Keeting PE: Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sei USA 86:854-857, 1989.
27. Sands R, Studd JWW: Exogenous androgens in postmenopausal women. Am J Med 98:76S-79S, 1995.
28. Garnett T, Studd J, Watson N, et al: The effects of plasma estradiol levels on increases in vertebral and femoral bone density following therapy with estradiol and estradiol with testosterone implants. Obstet Gynecol 79:968-972, 1992.
29. Watts NB, Notelovitz M, Timmons MC, et al: Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol 85:529-537, 1995.
30. Burger HG, Hailes J, Menelaus M, et al: The management of persistent menopausal symptoms with oestradiol-testosterone implants: clinical, lipid and hormonal results. Maturitas 6:351-358, 1984.
31. Cardozo L, Gibb DMF, Tuck SM, et al: The effects of subcutaneous hormone implants during the climacteric. Maturitas 5:177-184, 1984.
32. Montgomery JC, Appleby L, Brincat M, et al: Effect of oesterogen and testosterone implants on psychological disorders in the climacteric. Lancet l(8528):297-299, 1987.
33. Barlow H, Abdalla HI, Roberts ADG, et al: Long-term hormone implant therapy-hormonal and clinical effects. Obstet Gynecol 67:321-325, 1986.
34. Dow MGT, Hart DM, Forrest CA: Hormonal treatments of sexual unresponsiveness in postmenopausal women: a comparative study. Br J Obstet Gynaecol 90:361-366, 1983.
35. Danner C, Frick J: Androgen substitution with testosterone containing nasal drops. Int J Andiol 3:429-435, 1980.
36. Findlay JC, Place VA, Synder PJ: Transdermal delivery of testosterone. J Clin Endocrinol Metab 64:266-268, 1987.
37. Goldfarb S: Sex hormones and hepatic neoplasia. Cancer Res 36:2584-2588, 1976.
38. Westaby D, Paradinas FJ, Ogle SJ, et al: Liver damage from long-term methyltestosterone. Lancet 2(8032):262-263, 1977.
39. Farrell GC, Uren RF, Perkins KW et al: Androgeninduced hepatoma. Lancet l(7904):430-432, 1975.
40. Hickok LR, Toomey C, Speroff L: A comparison of esterified estrogens with and without methyltestosterone: Effects on endometrial histology and serum lipoproteins in postmenopausal women. Obstet Gynecol 82:919-924, 1993.
41. Wild RA: Obesity, lipids, cardiovascular risk, and androgen excess. Am JMed 98:27S-32S, 1995.
42. Tseng L, Mazella J, Mann WJ, et al: Estrogen synthesis in normal and malignant human endometrium. J Clin Endocrinol Metab 55:1029-1031, 1982.
43. Gumming C, Rebar RW, Hopper BR, et al: Evidence for an influence of the ovary in circulating dehydroepiandrosterone sulfate levels. J Clin Endociinol Metab 54:1069-1071, 1982.
44. Casson PR, Kristiansen SB, Umstot E, et al: Ovarian hyperstimulation augments adrenal dehydroepiandrosterone sulfate secretion. Fertil Steril 65(5):950-953, 1996.
45. Ditkoff EC, Fruzzetti F, Chang L, et al: The impact of estrogen on adrenal androgen sensitivity and secretion in polycystic ovary syndrome. J Clin Endocrinol Metab 80:603-605, 1995.
46. Thoman ML, Weigle WO: The cellular and subcellular bases of immunosenescence. Adv Immunol 46:221-261, 1989.
47. Daynes RA, Dudley DJ, Araneo BA: Regulation of murine lymphokine production in vivo: dehydroepiandrosterone is a natural enhancer of interleukin 2 synthesis by helper T cells. Eur J Immunol 20:793-802, 1990.
48. Garg M, Bondada S: Reversal of age-associated decline in immune response to pnu-imune vaccine by supplementation with the steroid hormone dehydroepiandrosterone. Infect Immunol 61:2238-2241, 1993.
49. Schwartz AG, Pashko LL: Cancer chemoprevention with the adrenocortical steroid dehydroepiandrosterone and structural analogs. J Cell Biochem 17 G: 73-79, 1993.
50. Suzuki T, Suzuki N, Daynes RA, Engleman EG: Dehydroepiandrostenedine enhances IL-2 production and cytotoxic effector function of human T cells. Clin Immunol Immunopathol 61:202-211, 1991.
51. Taggart DP, Gray CE, Bowman A, et al: Serum androgens and gonadotrophins in bronchial carcinoma. Respir Med 87:455-460, 1993.
52. Stahl F, Schnorr D, Pilz C, et al: Dehydroepiandrosterone (DHEA) levels in patients with prostatic cancer, heart diseases and under surgery stress. Exp Clin Endocrinol 99:68-70, 1992.
53. Zumoff B, Levin J, Rosenfeld RS, et al: Abnormal 24hr mean plasma concentrations of dehydroisoandrosterone and dehydroepiandrosterone sulfate in women with primary operable breast cancer. Cancer Res 41:3360-3363, 1981.
54. Merril R, Harrington G, Sunderland T: Plasma dehydroepiandrosterone levels in HIV infection. J Am Med Assoc 261:1149, 1989.
55. Casson PR, Andersen RN, Herrod HG, et al: Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am J Obstet Gynecol 169:1536-1539, 1993.
56. Barrett-Connor E, Khaw KT, Yen SSC: A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 215:1519-1524, 1986.
57. Casson PR, Hornsby PJ, Buster JE: Adrenal androgens, insulin resistance and cardiovascular disease. Sem Reprod Endocrinol 14(l):29-34, 1996.
58. Eich DM, Nestler JE, Johnson DE, et al: Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation 87:261-269, 1993.
59. Gordon GB, Bush DE, Weisman HF: Reduction of atherosclerosis by administration of dehydroepiandrosterone. J Clin Invest 82:712-720, 1988.
60. Lesse RL: The effects of DHEA on atherogenesis and platelet function, in Ann NY Acad Sei 774:281-291, 1995.
61. Coleman DL, Leiter EH, Schwizer RW: Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice. Diabetes 31:830-833, 1982.
62. MacEwen EG, Kurzman ID: Obesity in the dog: role of the adrenal steroid dehydroepiandrosterone (DHEA). JNutr 121:551-555, 1991.
63. Buffington CK, Pourmotabbed G, Kitabchi AE: Case report: amelioration of insulin resistance in diabetes with dehydroepiandrosterone. Am J Med Sei 306:320-324, 1993.
64. Schriock ED, Buffington CK, Givens JR, et al: Enhanced post-receptor insulin effects on women following dehydroepiandrosterone infusion. J Soc Gynecol Invest 1:74-78, 1994.
65. Casson PR, Faquin LC, Stentz FB, et al: Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. Fertil Sten763(5):1027-1031, 1995.
66. Bates GW, Egerman RS, Umstot ES, et al: Dehydroepiandrosterone attenuates study-induced declines in insulin sensitivity in postmenopausal women. Ann NY Acad Sei 774:291-293, 1995.
67. Morales AJ, Nolan JJ, Nelson JC, et al: Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 78:1360-1367, 1994.
68. Mortola J, Yen SSC: The effects of dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab 71:696-704, 1990.
69. Nestler JE, Barlascini CO, Clore JN, et al: Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab 66:57-61, 1988.
70. Usiskin KS, Butterworth S, Clore JN, et al: Lack of effect of dehydroepiandrosterone in obese men. Int J Obes 14:457-463, 1990.
71. Zumoff B, Strain GW, Heymsfield SB, et al: A randomized double-blind crossover study of the antiobesity effects of etiocholanolone. Obes Res 2:13-18, 1994.
72. Berkman LF, Seeman TE, Albert M, et al: High, usual and impaired functioning in communitydwelling older men and women: findings from the MacArthur foundation research network on successful aging. J Clin Epidemiol 46:1129-1140, 1993.
73. Flood JF, Roberts E: Dehydroepiandrosterone sulfate improves memory in aging mice. Brain Res 448:178-181, 1988.
74. Melchior CL, Ritzmann RF: Dehydroepiandrosterone is an anxiolytic in mice on the plus maze. Pharmacol Biochem Behav 47:437-441, 1994.
75. Robel P, Baulieu EE: Neurosteroids: biosynthesis and function. Trends Endocrinol Metab 5:1-8, 1994.
76. Roberts E: Dehydroepiandrosterone (DHEA) and its sulfate (DHEAS) as neutral facilitators: effects on brain tissue in culture and on memory in young and old mice. A cyclic GMP hypothesis of action of
77. DHEA and DHEAS in nervous system and other tissues, in Kalimi M, Regelson W (eds): The Biologic Role of Dehydroepiandrosterone (DHEA). Berlin, Walter de Gruyter, pp 13-42, 1990.
78. Friess E, Trachsel L, Guldner J, et al: DHEA administration increases rapid eye movement sleep and EEG power in the sigma frequency range. Am J Physiol 268:E107-E113, 1995.
79. Buster JE, Casson PR, Straughn AB, et al: Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionality studies. Am J Obstet Gynecol 166:1163-1170, 1992.
80. Casson PR, Straughn AB, Umstot ES: Delivery of dehydroepiandrosterone (DHEA) to premenopausal women: effects of micronization and non-oral administration. Am J Obstet Gynecol 174:649-653, 1996.
81. Rao MS, Subbarao V, Yeldandi AV, et al: Hepatocarcinogenicity of dehydroepiandrosterone in the rat. Cancer Res 52:2977-2979, 1992.